145 related articles for article (PubMed ID: 10815893)
1. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
2. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
Visonneau S; Cesano A; Torosian MH; Santoli D
Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Duval L; Schmidt H; Kaltoft K; Fode K; Jensen JJ; Sorensen SM; Nishimura MI; von der Maase H
Clin Cancer Res; 2006 Feb; 12(4):1229-36. PubMed ID: 16489078
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
6. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
7. Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study.
Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Zorsky P; Klug P; Dai L; Hussain M; Thomas AA; Sundaramurthy C
Immunol Invest; 2009; 38(8):820-38. PubMed ID: 19860591
[TBL] [Abstract][Full Text] [Related]
8. Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study.
Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Zorsky P; Klug P; Dai L; Hussain M; Thomas AA; Sundaramurthy C
Immunol Invest; 2010; 39(6):570-86. PubMed ID: 20653425
[TBL] [Abstract][Full Text] [Related]
9. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
10. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
Cesano A; Visonneau S; Santoli D
Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
[TBL] [Abstract][Full Text] [Related]
12. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
15. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
16. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
17. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
18. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
20. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
